Novel Therapeutic Milestone in the Treatment of Alzheimer’s Disease: Dawn of a New Era? – A GameOn! Challenge

Author(s)/Faculty: Sharon Cohen, MD, FRCPC; Raymond Scott Turner, PhD, MD, FAAN, FANA
Release Date: 4/30/2022Expiration Date: 4/29/2023
Credit Type: CME / CME with ABIM MOCNumber of Credits: 0.5
Content Type: GamingProvider:
Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living, accounting for 60% to 80% of all dementia. More than 5 million Americans are living with AD, and by 2050, this number is projected to rise to 14 million. Despite this significant burden, the currently approved treatments are symptomatic drugs that do not stop or delay the progression of the disease. Recently, the FDA approved a novel therapy - the first and only AD treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. The latest evidence of emerging treatment options suggests that early identification of patients is necessary to optimize outcomes. Thus, neurologists, primary care physicians, and other healthcare professionals who provide care for patients with AD require timely education on the recent therapeutic advances and strategies for the early identification and management of patients with AD.